CN102388151A - 用于鉴定、分类和监控具有bcl-2家族抑制剂抗性肿瘤和癌症的受试者的方法和组合物 - Google Patents

用于鉴定、分类和监控具有bcl-2家族抑制剂抗性肿瘤和癌症的受试者的方法和组合物 Download PDF

Info

Publication number
CN102388151A
CN102388151A CN2010800160886A CN201080016088A CN102388151A CN 102388151 A CN102388151 A CN 102388151A CN 2010800160886 A CN2010800160886 A CN 2010800160886A CN 201080016088 A CN201080016088 A CN 201080016088A CN 102388151 A CN102388151 A CN 102388151A
Authority
CN
China
Prior art keywords
sample
gene
patient
bcl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800160886A
Other languages
English (en)
Chinese (zh)
Inventor
M.F.范德尔夫特
D.黄
C.谢
D.塞米扎罗夫
T.尤奇尔
R.R.列斯尼夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter and Eliza Hall Institute of Medical Research
Abbott Laboratories Ltd
Original Assignee
Inst Medical W & E Hall
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Medical W & E Hall, Abbott GmbH and Co KG filed Critical Inst Medical W & E Hall
Publication of CN102388151A publication Critical patent/CN102388151A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN2010800160886A 2009-02-11 2010-02-11 用于鉴定、分类和监控具有bcl-2家族抑制剂抗性肿瘤和癌症的受试者的方法和组合物 Pending CN102388151A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15174909P 2009-02-11 2009-02-11
US61/151749 2009-02-11
PCT/US2010/023818 WO2010093742A1 (en) 2009-02-11 2010-02-11 Methods and compositions for identifying, classifying and monitoring subject having bcl-2 family inhibitor-resistant tumors and cancers

Publications (1)

Publication Number Publication Date
CN102388151A true CN102388151A (zh) 2012-03-21

Family

ID=42112120

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800160886A Pending CN102388151A (zh) 2009-02-11 2010-02-11 用于鉴定、分类和监控具有bcl-2家族抑制剂抗性肿瘤和癌症的受试者的方法和组合物

Country Status (7)

Country Link
US (2) US9045800B2 (enExample)
EP (1) EP2396427A1 (enExample)
JP (2) JP2012517241A (enExample)
CN (1) CN102388151A (enExample)
CA (1) CA2751293A1 (enExample)
MX (1) MX2011008488A (enExample)
WO (1) WO2010093742A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107315088A (zh) * 2012-05-10 2017-11-03 尤特罗皮克斯制药股份有限公司 对癌症的代理功能性诊断测试
IN2014DN11205A (enExample) 2012-06-20 2015-10-02 Eutropics Pharmaceuticals Inc
EP2922544B1 (en) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
WO2015017788A1 (en) 2013-08-01 2015-02-05 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
AU2014342269B2 (en) 2013-10-30 2020-02-27 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
HK1247250A1 (zh) 2015-01-12 2018-09-21 Eutropics Pharmaceuticals, Inc. 用於指导癌症治疗的内容相关的诊断测试
JP6851978B2 (ja) 2015-04-20 2021-03-31 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ミトコンドリアプロファイリングによるアルボシジブ応答の予測
JP6510075B2 (ja) 2015-05-18 2019-05-08 トレロ ファーマシューティカルズ， インコーポレイテッド バイオアベイラビリティが高いアルボシジブプロドラッグ
EP3331510A4 (en) 2015-08-03 2019-04-03 Tolero Pharmaceuticals, Inc. COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
AU2017305508B2 (en) 2016-08-05 2021-01-07 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CA3047557A1 (en) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
TWI725488B (zh) 2018-07-31 2021-04-21 大陸商蘇州亞盛藥業有限公司 Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途
CN114522167A (zh) 2018-07-31 2022-05-24 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
EP3672594B1 (en) 2018-07-31 2021-09-29 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
AU2019315466B2 (en) 2018-07-31 2022-05-19 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
EP3758005A1 (en) * 2019-06-24 2020-12-30 Koninklijke Philips N.V. Identification of the cellular function of an active nfkb pathway
WO2025136456A1 (en) * 2023-07-14 2025-06-26 Eil Therapeutics, Inc. Compounds having ((3-nitrophenyl)sulfonyl)acetamide as bcl-2 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030191300A1 (en) * 1998-10-07 2003-10-09 Bennett C. Frank Antisense modulation of bcl-x expression
WO2008082673A2 (en) * 2006-12-28 2008-07-10 Abbott Laboratories Companion diagnostic assays for cancer therapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8108820A (pt) 1980-09-24 1982-08-24 Cetus Corp Processo e sonda de diagnostico
ATE53862T1 (de) 1982-01-22 1990-06-15 Cetus Corp Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5756696A (en) 1986-01-16 1998-05-26 Regents Of The University Of California Compositions for chromosome-specific staining
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
US5231020A (en) 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5491224A (en) 1990-09-20 1996-02-13 Bittner; Michael L. Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture
US5464746A (en) 1991-12-17 1995-11-07 Abbott Laboratories Haptens, tracers, immunogens and antibodies for carbazole and dibenzofuran derivatives
US5424414A (en) 1991-12-17 1995-06-13 Abbott Laboratories Haptens, tracers, immunogens and antibodies for 3-phenyl-1-adamantaneacetic acids
US6395472B1 (en) 1999-02-05 2002-05-28 Abbott Laboratories Methods of utilizing the TT virus
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
CN1834261A (zh) * 2005-11-15 2006-09-20 北京博奥生物芯片有限责任公司 基因分型芯片及其制备方法与应用
US20080233567A1 (en) * 2006-09-05 2008-09-25 Murray William E Companion diagnostic assays for cancer therapy
CN102203788B (zh) 2008-10-31 2015-05-20 Abbvie公司 用于装配成小组的癌细胞系以用于测试一种或多种药物组合物的功效的方法
JP6812855B2 (ja) 2017-03-10 2021-01-13 Jnc株式会社 ジアルキルアミノシランの製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030191300A1 (en) * 1998-10-07 2003-10-09 Bennett C. Frank Antisense modulation of bcl-x expression
WO2008082673A2 (en) * 2006-12-28 2008-07-10 Abbott Laboratories Companion diagnostic assays for cancer therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARK F VAN DELFT ET AL: "《The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized》", 《CANCER CELL》, vol. 10, no. 5, 1 November 2006 (2006-11-01) *
TILMAN OLTERSDORF ET AL: "《An inhibitor of BCL-2 family proteins induces regression of solid tumours》", 《NATURE》, vol. 435, 2 June 2005 (2005-06-02) *

Also Published As

Publication number Publication date
EP2396427A1 (en) 2011-12-21
WO2010093742A1 (en) 2010-08-19
US20150211075A1 (en) 2015-07-30
CA2751293A1 (en) 2010-08-19
JP2016047044A (ja) 2016-04-07
US9045800B2 (en) 2015-06-02
JP2012517241A (ja) 2012-08-02
WO2010093742A8 (en) 2011-08-11
MX2011008488A (es) 2011-10-24
US20100234239A1 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
US9045800B2 (en) Methods and compositions for identifying, classifying and monitoring subject having Bcl-2 family inhibitor-resistant tumors and cancers
CN102216775B (zh) 对hsp90-抑制剂的易感性
US20080193943A1 (en) Companion diagnostic assays for cancer therapy
CN101611154A (zh) 用于癌症治疗的成对诊断测定
JP6106257B2 (ja) 非小細胞肺癌の予後を決定するための診断方法
US20080014579A1 (en) Gene expression profiling in colon cancers
WO2008082643A2 (en) Companion diagnostic assays for cancer therapy
EP2479288A1 (en) Markers to predict and monitor response to Aurora kinase B inhibitor therapy
TWI770503B (zh) 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物
US20100028889A1 (en) Companion diagnostic assays for cancer therapy
US20080233567A1 (en) Companion diagnostic assays for cancer therapy
US20170342504A1 (en) Early ovarian cancer detection diagnostic test based on mrna isoforms
US20080269067A1 (en) Companion diagnostic assays for cancer therapy
US20160153052A1 (en) Marker to predict and monitor response to aurora kinase b inhibitor therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ABBOTT HOSPITAL CO., LTD.

Free format text: FORMER OWNER: ABBOTT GMBH. + CO. KG

Effective date: 20140613

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Bahamas Nassau

Applicant after: AbbVie Inc.

Applicant after: THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

Address before: Bahamas Nassau

Applicant before: Abbott Laboratories Ltd.

Applicant before: THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: ABBOTT HOSPITAL CO., LTD. TO: ABBVIE BAHAMAS B.V.

TA01 Transfer of patent application right

Effective date of registration: 20140613

Address after: Bahamas Nassau

Applicant after: Abbott Laboratories Ltd.

Applicant after: THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

Address before: Illinois State

Applicant before: ABBOTT LABORATORIES

Applicant before: THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120321